- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00262067
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Geelong, Australia, 3220
-
Malvern, Australia, 3144
-
Melbourne, Australia, 3002
-
Perth, Australia, 6008
-
Southport, Australia, 4215
-
Wahroonga, Australia, 2076
-
Waratah, Australia, 2298
-
Wollongong, Australia, 2500
-
-
-
-
-
Porto Alegre, Brasile, 91350-200
-
Rio de Janeiro, Brasile, 22260-020
-
Salvador, Brasile, 40170-110
-
Santo Andre, Brasile, 09060-870
-
Sao Paulo, Brasile, 03102-002
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1S6
-
Montreal, Quebec, Canada, H2L 4M1
-
-
-
-
-
Kyunggi-do, Corea, Repubblica di, 411-769
-
Seoul, Corea, Repubblica di, 110-744
-
Seoul, Corea, Repubblica di, 120-752
-
-
-
-
-
Chelyabinsk, Federazione Russa, 454 087
-
Ivanovo, Federazione Russa, 153040
-
Kazan, Federazione Russa, 420029
-
Kazan, Federazione Russa, 420111
-
Moscow, Federazione Russa, 115478
-
Moscow, Federazione Russa, 129128
-
Moscow, Federazione Russa, 117837
-
Novosibirsk, Federazione Russa, 630047
-
Obninsk, Federazione Russa, 249036
-
Ryazan, Federazione Russa, 390011
-
Samara, Federazione Russa, 443066
-
St Petersburg, Federazione Russa, 197758
-
UFA, Federazione Russa, 450054
-
-
-
-
-
Quezon City, Filippine, 1114
-
-
-
-
-
Marseille, Francia, 13273
-
Paris, Francia, 75248
-
Reims, Francia, 51100
-
Saint Herblain, Francia, 44805
-
Strasbourg, Francia, 67010
-
-
-
-
-
Athens, Grecia, 11521
-
Hania, Grecia, 73300
-
Heraklion, Grecia, 71110
-
Patras, Grecia, 26500
-
Thessaloniki, Grecia, 57001
-
-
-
-
-
Guatemala City, Guatemala, 01015
-
-
-
-
-
Acapulco, Messico, 39670
-
Aguascalientes, Messico, 20230
-
Merida, Messico, 97500
-
Monterrey, Messico, 64020
-
Monterrey, Messico, 64380
-
-
-
-
-
Oslo, Norvegia, 0407
-
Oslo, Norvegia, 0310
-
-
-
-
-
Amstelveen, Olanda, 1186 AH
-
Apeldoorn, Olanda, 7334 DZ
-
Delft, Olanda, 2600 GA
-
-
-
-
-
Panama City, Panama
-
-
-
-
-
Callao, Perù
-
-
-
-
-
Chelsmford, Regno Unito, CM1 7ET
-
Cottingham, Regno Unito, HU16 5JQ
-
Epping, Regno Unito, CM16 6TN
-
Huddersfield, Regno Unito, HD3 3EA
-
Nottingham, Regno Unito, NG5 1PB
-
Sheffield, Regno Unito, S1O 2SJ
-
Swansea, Regno Unito, SA2 8QA
-
-
-
-
-
Singapore, Singapore, 119228
-
Singapore, Singapore, 169610
-
-
-
-
-
Córdoba, Spagna, 14004
-
Elche, Spagna, 03203
-
Girona, Spagna, 17007
-
La Coruna, Spagna, 15006
-
La Laguna, Spagna, 38320
-
Madrid, Spagna, 28034
-
Santander, Spagna, 39008
-
Sevilla, Spagna, 41013
-
Valencia, Spagna, 46010
-
Zaragoza, Spagna, 50009
-
-
-
-
California
-
Fullerton, California, Stati Uniti, 92835
-
Santa Barbara, California, Stati Uniti, 93105
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
-
Sioux City, Iowa, Stati Uniti, 51101
-
-
Kansas
-
Wichita, Kansas, Stati Uniti, 67214-3728
-
-
-
-
-
Gaevle, Svezia, 80187
-
Uppsala, Svezia, 751 85
-
Örebro, Svezia, 701 85
-
-
-
-
-
Tainan, Taiwan, 704
-
Taoyuan, Taiwan, 333
-
-
-
-
-
Cherkassy, Ucraina, 18009
-
Dnipropetrovsk, Ucraina, 49102
-
Kiev, Ucraina, 03115
-
Lvov, Ucraina, 79031
-
Odessa, Ucraina, 65055
-
Zaporozhye, Ucraina, 69104
-
-
-
-
-
Montevideo, Uruguay, 11200
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease.
- Signed Informed Consent Form.
- Age ≥ 18 years.
- For women of childbearing potential, use of accepted and effective method of non-hormonal contraception.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Ability and capacity to comply with study and follow-up procedures.
- For anthracycline cohort only: Adequate left ventricular function at study entry, defined as a left ventricular ejection fraction (LVEF) ≥ 50% by either multigated acquisition (MUGA) scan scan or echocardiography (ECHO).
- For subjects who have received recent radiation therapy, recovery prior to baseline (Day 0) from any significant (Grade ≥ 3) acute toxicity.
Exclusion Criteria:
- Unknown human epidermal growth factor receptor 2 (HER2) status or known HER2-positive status.
- Prior chemotherapy for locally recurrent or metastatic disease.
- Prior hormonal therapy less than 1 week prior to Day 0.
- Prior adjuvant or neoadjuvant chemotherapy within 12 months prior to Day 0.
- For anthracycline cohort only: Prior anthracycline as part of neoadjuvant or adjuvant therapy for localized breast cancer.
- Investigational therapy within 28 days of Day 0.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study.
- Minor surgical procedures, such as fine needle aspirations or core biopsies, within 7 days prior to Day 0.
- Prior therapy with bevacizumab, sorafenib, sunitinib, or other vascular endothelial growth factor (VEGF) pathway-targeted therapy.
- Known brain or other central nervous system (CNS) metastases.
- Blood pressure of > 150/100 mmHg.
- Unstable angina.
- New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF).
- History of myocardial infarction within 6 months prior to Day 0.
- History of stroke or transient ischemic attack within 6 months prior to Day 0.
- Clinically significant peripheral vascular disease.
- Evidence of bleeding diathesis or coagulopathy.
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0.
- Serious non-healing wound, ulcer, or bone fracture.
- Pregnancy (positive serum pregnancy test) or lactation.
- Inadequate organ function, as evidenced by any of the following laboratory values: Absolute neutrophil count < 1500/uL; platelet count < 100,000/uL; total bilirubin > 1.5 mg/dL; alkaline phosphatase, AST, and/or ALT > 2x upper limit of normal (ULN) (> 5x ULN in subjects with known liver or, for alkaline phosphatase elevations, bone involvement); alkaline phosphatase > 2x ULN (> 7x ULN in subjects with known bone involvement); serum creatinine > 2.0 mg/dL; partial thromboplastin time (PTT) and/or either international normalized ratio (INR) or prothrombin time (PT) > 1.5x upper limit of normal (except for subjects receiving anti-coagulation therapy); urine protein/creatinine ratio > 1.0 at screening for U.S. subjects, or urine dipstick for proteinuria >/= 1+ at screening followed by 24-hour urine collection demonstrating > 1 g protein/24 hr for ex-U.S. subjects.
- Uncontrolled serious medical or psychiatric illness.
- Active infection requiring intravenous (iv) antibiotics at Day 0.
- History of other malignancies within 5 years of Day 0 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix (subjects with a history of bilateral breast cancer will be eligible).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Bevacizumab + chemotherapy
Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
|
Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months.
The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study.
The initial dose was delivered over 90±10 minutes.
If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes.
If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
Altri nomi:
The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles. Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle
Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle
Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle |
Comparatore placebo: Placebo + chemotherapy
Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
|
The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles. Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle
Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle
Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle
Placebo consisted of the vehicle for bevacizumab without the antibody.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Lasso di tempo: Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.
For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions.
For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.
Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically.
All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.
|
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Lasso di tempo: Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
An objective response was defined as a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart as determined by the investigator using RECIST.
For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.
|
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
Duration of Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Lasso di tempo: Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
Duration of objective response was defined as the time from the first tumor assessment that led to a determination of an objective response to the time of disease progression or death due to any cause, whichever occurred first.
|
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
Overall Survival
Lasso di tempo: Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
|
Overall survival was defined as the time from randomization until death from any cause.
|
Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
|
1-year Survival
Lasso di tempo: Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
|
1-year survival was defined as the percentage of patients who were alive 1 year after randomization. The percentage of patients alive at 1 year was determined using Kaplan-Meier analyses and the 95% confidence intervals were computed using the Brookmeyer-Crowley method. |
Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
|
Progression-free Survival (PFS) as Determined by the Independent Review Committee Using Response Evaluation Criteria in Solid Tumors (RECIST)
Lasso di tempo: Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the Independent Review Committee using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.
|
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Leonardo Faoro, MD, Genentech, Inc.
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie della pelle
- Neoplasie
- Neoplasie per sede
- Malattie del seno
- Neoplasie mammarie
- Effetti fisiologici delle droghe
- Agenti antineoplastici
- Agenti antineoplastici, immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Bevacizumab
Altri numeri di identificazione dello studio
- AVF3694g
- BO20094 (Altro identificatore: Hoffmann-La Roche)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro al seno metastatico
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University e altri collaboratoriCompletatoLa guida all'applicazione clinica di Conebeam Breast CTCina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
Prove cliniche su Bevacizumab
-
National Cancer Institute (NCI)Attivo, non reclutanteCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Cistodenocarcinoma ovarico a cellule chiare | Adenocarcinoma endometrioide ovarico | Cistodenocarcinoma sieroso ovarico | Adenocarcinoma endometriale a cellule chiare | Adenocarcinoma... e altre condizioniStati Uniti
-
M.D. Anderson Cancer CenterReclutamentoCarcinoma epatocellulare in stadio IB AJCC v8 | Carcinoma epatocellulare in stadio II AJCC v8 | Carcinoma epatocellulare resecabile | Carcinoma epatocellulare stadio I AJCC v8 | Stadio IA Carcinoma epatocellulare AJCC v8Stati Uniti
-
National Cancer Institute (NCI)CompletatoAdenocarcinoma cervicale | Carcinoma adenosquamoso cervicale | Carcinoma a cellule squamose della cervice, non altrimenti specificato | Stadio IVA Cancro cervicale AJCC v6 e v7 | Carcinoma cervicale ricorrente | Cancro cervicale in stadio IV AJCC v6 e v7 | Stadio IVB Cancro cervicale AJCC v6 e v7Stati Uniti
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)ReclutamentoCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Adenocarcinoma endometrioide ovarico | Adenocarcinoma ovarico a cellule chiare | Adenocarcinoma della tuba di Falloppio | Adenocarcinoma sieroso delle tube di Falloppio | Adenocarcinoma... e altre condizioniStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteMelanoma cutaneo di stadio IV AJCC v6 e v7 | Melanoma cutaneo in stadio IIIC AJCC v7 | Melanoma non resecabileStati Uniti
-
National Cancer Institute (NCI)NRG OncologyCompletatoGlioblastoma | Gliosarcoma | Glioblastoma ricorrente | Oligodendrogliomi | Glioblastoma a cellule giganti | Neoplasia cerebrale ricorrenteStati Uniti, Canada
-
National Cancer Institute (NCI)ReclutamentoSarcoma metastatico della parte molle alveolare | Sarcoma della parte molle alveolare non resecabileStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteAdenocarcinoma endometrioide ovarico | Adenocarcinoma sieroso peritoneale primario di alto grado | Adenocarcinoma endometrioide delle tube di Falloppio | Carcinoma delle tube di Falloppio resistente al platino | Carcinoma peritoneale primario resistente al platino | Adenocarcinoma sieroso ovarico... e altre condizioniStati Uniti, Canada
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletatoCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Carcinoma delle tube di Falloppio resistente al platino | Carcinoma peritoneale primario resistente al platino | Carcinoma ovarico resistente al platino | Carcinoma ovarico... e altre condizioniStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteGlioblastoma ricorrenteStati Uniti